Additionally, this group demonstrated that tumor cell expression of the alarmin IL-33 was necessary and sufficient for eosinophil-mediated anti-tumor responses and that this mechanism enhanced the efficacy of immune checkpoint inhibitors. The gene discussed is IL33; the disease is neoplasm.